CMPS, US20451W1018

November 3 results are due for COMPASS Pathways stock, up 55.80 percent year to date

Published on 10/17/2026 at 22:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market capitalization was USD 1.5 billion on October 16, 2026. Compass Pathways stock was last EUR 9.70 on October 16, 2026, down 6.73 percent on Tradegate.

Dates and market position

Compass Pathways is scheduled to report results on November 3, 2026.
The stock stood 55.80 percent higher year to date on October 16, 2026.
Compass Pathways stock was last at EUR 9.70 on October 16, 2026 at 8:01 p.m. CEST, down 6.73 percent on Tradegate.
Market capitalization stood at USD 1.5 billion on October 16, 2026.

CMPS, US20451W1018, Illustration mit AI erstellt.

Compass Pathways stock is heading toward its next scheduled results date on November 3, 2026, while its year-to-date gain stood at 55.80 percent on October 16, 2026. MetaCap lists November 3, 2026 as the next reporting date. The last available Tradegate quotation stood at EUR 9.70 on October 16, 2026 at 8:01 p.m. CEST, down 6.73 percent on that venue.

Results date sets the next checkpoint

The November reporting date gives investors the next concrete test for Compass Pathways' development story. The company is developing COMP360, an investigational synthetic psilocybin treatment for treatment-resistant depression and post-traumatic stress disorder, according to Compass Pathways.

The company says COMP360 has Breakthrough Therapy designation from the U.S. Food and Drug Administration and that its late-stage program includes a trial for post-traumatic stress disorder. Those development milestones frame the November date, but they do not replace the need for fresh financial and clinical updates.

Price remains inside the yearly range

On the Nasdaq, CMPS closed at USD 10.75 on October 16, 2026 at 4:00 p.m. EDT. The 52-week range was USD 4.88 to USD 15.87, leaving the stock 32.30 percent below its yearly high and 120.30 percent above its yearly low. Trading volume was 2.69 million shares against an average of 2.78 million.

The October 16 Tradegate quotation gives German investors a euro view of the same stock. The EUR 9.70 level was 6.73 percent below the preceding Tradegate reference, while the Nasdaq close provides the separate home-market context in USD.

Valuation ahead of November 3

Market capitalization stood at USD 1.5 billion on October 16, 2026. The company reported no dividend yield, and trailing earnings were negative, so a conventional price-to-earnings comparison does not provide a useful positive ratio.

Compass Pathways is headquartered in London and has a U.S. office in New Jersey. Its pipeline remains centered on mental-health treatments, with COMP360 as the lead program and the November 3 reporting date as the next scheduled investor checkpoint.

Price and investor calendar

The next dated milestone is November 3, 2026, when Compass Pathways is scheduled to report results. Until then, the most concrete market markers are the EUR 9.70 Tradegate quotation, the USD 10.75 Nasdaq close and the 52-week range from USD 4.88 to USD 15.87.

Market context is best read alongside the company's clinical timetable and the year-to-date move. The stock's 55.80 percent gain through October 16, 2026 leaves the November update as the next event capable of changing the market's assessment of the development program.